The Efficacy of Safinamide in the Management of Parkinson's Disease: A Systematic Review

Sharaf, Joudi; Williams, Kerry-Ann D; Tariq, Maha; Acharekar, Maitri V; Saldivia, Sara Elena Guerrero; Unnikrishnan, Sumedha; Chavarria, Yeny Y; Akindele, Adebisi O; Jalkh, Ana P; Eastmond, Aziza K; Shetty, Chaitra; Rizvi, Syed Muhammad Hannan Ali; Mohammed, Lubna

doi:10.7759/cureus.29118

Cited by 3 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pain is a frequent complaint among individuals with PD. 26 It is very frequently observed in fluctuating PD patients during OFF periods, and in these circumstances, it improves with strategies that provide more continuous dopamine stimulation (studio recover with rotigotine). 31 However, other central dopamine-independent mechanisms can be involved in the appearance of pain.…”

Section: Methodsmentioning

confidence: 99%

“…25 Interestingly, in addition to enhancing the striatal dopamine content, safinamide has the potential to modulate glutamate release from the cortico-striatal pathway, and hypothetically might contribute to alleviating depressive symptoms. 26 Furthermore, anxiety, another commonly observed NMS in PD with a significant impact on QoL, might share a similar pathophysiological mechanism as depression.…”

Section: Dovepressmentioning

confidence: 99%

See 1 more Smart Citation

Impact of Safinamide on Patient-Reported Outcomes in Parkinson’s Disease

Espinoza-Vinces,

Villino-Rodríguez,

Atorrasagasti-Villar

et al. 2023

PROM

View full text Add to dashboard Cite

Introduction Parkinson’s disease (PD) is a chronic and progressive neurodegenerative condition due to the degeneration of nigral dopaminergic cells. Both motor and non-motor symptoms (NMS) of PD produce a marked impairment in PD patients’ quality of life (QoL), but contrary to motor features, NMS do not improve with dopamine replacement. Novel therapeutic interventions for PD have successfully controlled most motor manifestations of PD, but the management of NMS is still challenging. Since NMS have a negative impact on the QoL of PD patients, researchers are currently looking for drugs that can modulate the activity of neurotransmitter systems other than dopamine in the hope that can alleviate NMS in PD. Among the recently approved drugs for patients experiencing fluctuations in motor symptoms, safinamide stands out as an effective add-on therapy to levodopa. Safinamide is a monoamine oxidase type-B inhibitor (MAOB-I), with proven efficacy in reducing motor fluctuations. Its distinctive mechanism of action impacts dopaminergic pathways via MAOB inhibition and glutamatergic pathways by blocking sodium and calcium channels. Findings from Phase III clinical trials, meta-analysis, post-hoc analysis, and real-life experiences indicate that safinamide benefits motor symptoms such as tremor, bradykinesia, rigidity, and gait. Additionally, it shows promise for improving NMS like fatigue, pain, mood, and sleep disturbances in patients with PD. Areas Covered In this article, the authors explore the impact of safinamide on patient-reported outcomes in PD. A thorough search was conducted on PubMed focusing on studies published between 2018 and 2023 in English. The inclusion criteria encompassed clinical trials, randomized controlled trials, systematic reviews, meta-analyses, and reviews. The search strategy revolved around the implementation of MeSH terms related to safinamide and its impact on the quality of life in PD. Conclusion Our data strongly support the improving effect on QoL, reducing the disabling NMS reported in patients with PD.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Dovepressmentioning

confidence: 99%

Impact of Safinamide on Patient-Reported Outcomes in Parkinson’s Disease

Espinoza-Vinces,

Villino-Rodríguez,

Atorrasagasti-Villar

et al. 2023

PROM

View full text Add to dashboard Cite

show abstract

Insomnia in Parkinson’s Disease: Causes, Consequences, and Therapeutic Approaches

Duan,

Liu,

et al. 2024

Mol Neurobiol

View full text Add to dashboard Cite

Future Directions for Developing Non-dopaminergic Strategies for the Treatment of Parkinson’s Disease

Wamelen

Leta

Chaudhuri

et al. 2024

View full text Add to dashboard Cite

The symptomatic treatment of Parkinson’s disease (PD) has been dominated by the use of dopaminergic medication, but significant unmet need remains, much of which is related to non-motor symptoms and the involvement of non-dopaminergic transmitter systems. As such, little has changed in the past decades that has led to milestone advances in therapy and significantly improved treatment paradigms and patient outcomes, particularly in relation to symptoms unresponsive to levodopa. This review has looked at how pharmacological approaches to treatment are likely to develop in the near and distant future and will focus on two areas: 1) novel non-dopaminergic pharmacological strategies to control motor symptoms; and 2) novel non-dopaminergic approaches for the treatment of non-motor symptoms. The overall objective of this review is to use a ‘crystal ball’ approach to the future of drug discovery in PD and move away from the more traditional dopamine-based treatments. Here, we discuss promising non-dopaminergic and ‘dirty drugs’ that have the potential to become new key players in the field of Parkinson’s disease treatment.

show abstract

The Efficacy of Safinamide in the Management of Parkinson's Disease: A Systematic Review

Cited by 3 publications

References 32 publications

Impact of Safinamide on Patient-Reported Outcomes in Parkinson’s Disease

Impact of Safinamide on Patient-Reported Outcomes in Parkinson’s Disease

Insomnia in Parkinson’s Disease: Causes, Consequences, and Therapeutic Approaches

Future Directions for Developing Non-dopaminergic Strategies for the Treatment of Parkinson’s Disease

Contact Info

Product

Resources

About